Multiple Sclerosis (MS) Clinical Trial
— REHABSEPOfficial title:
Observational Study of the Physical Capacity of Patients With Multiple Sclerosis and Evaluation of the Effects of Usual Rehabilitation in the Day Hospital
The purpose of this study is to assess the physical capacity of patients with multiple sclerosis and the effects of rehabilitation, encompassing physical therapy and physical activity as it is carried out in the day hospital of (the Physical and Rehabilitation Medicine department) at Garches Hospital. We will compare the results of assessments carried out before and after a standard rehabilitation program.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | October 2015 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Multiple Sclerosis with EDSS = 6 (Expanded Disability Status Scale) - Patient = 18 years old - Patient able to comply with the recommended monitoring - No relapse within the last three months - More than six months elapsed since last medical care in day hospital - No recent modification (six month) of medications for MS - More than three months elapsed since last change of associated treatments (Fampyra, botulinum toxin) Exclusion Criteria: - Patients under any form of guardianship or curatorship - Breastfeeding - Orthopedic complications with repercussions on walking activities - No affiliation to a social security scheme (beneficiary or assignee) |
Observational Model: Cohort
Country | Name | City | State |
---|---|---|---|
France | Raymond Poincaré Hospital | Garches |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the strength and fatigue | Assessment realised with an isokinetic dynamometer | Within 10 weeks from the start of the rehabilitation program | No |
Secondary | 6 minutes walking test | Patients were instructed to walk as far as possible in a 50 meters corridor during 6 minutes | Within 10 weeks from the start of the rehabilitation program | No |
Secondary | Evaluation of aerobic capacity during an effort test | Aerobic capacity (VO2max) | Within 10 weeks from the start of the rehabilitation program | No |
Secondary | Assessment of the balance of patients | Berg Balance Scale | Within 10 weeks from the start of the rehabilitation program | No |
Secondary | Assessment of Spasticity with the Modified Ashworth Scale (MAS), | Within 10 weeks from the start of the rehabilitation program | No | |
Secondary | 10 meters Walk test | Patients have to walk over a 14 meter walkway and time required to traverse the middle 10 meters of the walk was recorded to avoid acceleration and deceleration effects | Within 10 weeks from the start of the rehabilitation | No |
Secondary | Timed up and go test | Patients have to get up from a chair, walk 3 meters, turn around and return to sitting as quickly as possible | Within 10 weeks from the start of the rehabilitation | No |
Secondary | Time to ascend and descend stairs | Participants were instructed to ascend and descend 10 stairs using the hand rail | Within 10 weeks from the start of the rehabilitation | No |
Secondary | Assessment of Strength with the Medical Research Council (MRC), | Within 10 weeks from the start of the rehabilitation | No | |
Secondary | Assessment of Quality of Life with SEP-59 Scale | Within 10 weeks from the start of the rehabilitation | No | |
Secondary | Assessment of the balance of patients | Postural control assessment : eyes opened and eyes closed | Within 10 weeks from the start of the rehabilitation | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05177523 -
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
|
||
Not yet recruiting |
NCT06053749 -
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
|
||
Not yet recruiting |
NCT06450600 -
Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education
|
N/A | |
Recruiting |
NCT04926818 -
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
|
Phase 3 | |
Not yet recruiting |
NCT03624296 -
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
|
N/A | |
Terminated |
NCT04203498 -
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
|
Phase 3 | |
Active, not recruiting |
NCT04602390 -
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT01804647 -
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
|
||
Terminated |
NCT04907305 -
Next-Gen MS: Feed-forward PRO Data for MS Research
|
||
Active, not recruiting |
NCT03456206 -
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
|
||
Completed |
NCT04705610 -
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
|
N/A | |
Completed |
NCT01366027 -
PRISM Registry: Pseudobulbar Affect Registry Series
|
N/A | |
Completed |
NCT03135249 -
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 | |
Recruiting |
NCT05633875 -
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
|
||
Completed |
NCT02612935 -
An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
|
N/A | |
Completed |
NCT02739542 -
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
|
Phase 4 | |
Completed |
NCT03177655 -
Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT04777539 -
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
|
||
Completed |
NCT02308579 -
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
|
N/A | |
Withdrawn |
NCT01710228 -
Alternative Treatment Paradigm for Natalizumab Trial
|
Phase 2 |